201 related articles for article (PubMed ID: 34754160)
21. Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer.
Skrzydlewska E; Sulkowska M; Wincewicz A; Koda M; Sulkowski S
World J Gastroenterol; 2005 Jul; 11(27):4225-9. PubMed ID: 16015694
[TBL] [Abstract][Full Text] [Related]
22. Cathepsin D content in colorectal cancer. Correlation with cathepsin D activity and other biological parameters: a preliminary report.
Tumminello FM; Gebbia N; Pizzolanti G; Russo A; Bazan V; Leto G
Oncology; 1995; 52(3):237-42. PubMed ID: 7715907
[TBL] [Abstract][Full Text] [Related]
23. Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study.
Kune GA; Kune S; Field B; White R; Brough W; Schellenberger R; Watson LF
Dis Colon Rectum; 1990 Nov; 33(11):938-46. PubMed ID: 2226081
[TBL] [Abstract][Full Text] [Related]
24. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
25. Stereologic estimates of volume-weighted mean nuclear volume in colorectal adenocarcinoma: correlation with histologic grading, Dukes' staging, cell proliferation activity and p53 protein expression.
Martín R; Nieto S; Santamaría L
Gen Diagn Pathol; 1997 Jul; 143(1):29-38. PubMed ID: 9269906
[TBL] [Abstract][Full Text] [Related]
26. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
27. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal cancer.
Ramcharan SK; Lip GY; Stonelake PS; Blann AD
Eur J Clin Invest; 2013 Aug; 43(8):801-8. PubMed ID: 23683169
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
29. Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study.
Mukai M; Ito I; Mukoyama S; Tajima T; Saito Y; Nakasaki H; Sato S; Makuuchi H
Oncol Rep; 2003; 10(4):927-34. PubMed ID: 12792747
[TBL] [Abstract][Full Text] [Related]
30. For patients with Dukes' B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis.
Caplin S; Cerottini JP; Bosman FT; Constanda MT; Givel JC
Cancer; 1998 Aug; 83(4):666-72. PubMed ID: 9708929
[TBL] [Abstract][Full Text] [Related]
31. Cathepsin B/cystatin C complex levels in sera from patients with lung and colorectal cancer.
Zore I; Krasovec M; Cimerman N; Kuhelj R; Werle B; Nielsen HJ; Brünner N; Kos J
Biol Chem; 2001 May; 382(5):805-10. PubMed ID: 11517934
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of microRNA-21 as a biomarker in each Dukes' stage of colorectal cancer.
Fukushima Y; Iinuma H; Tsukamoto M; Matsuda K; Hashiguchi Y
Oncol Rep; 2015 Feb; 33(2):573-82. PubMed ID: 25421755
[TBL] [Abstract][Full Text] [Related]
33. Improved procedure for determination of serum lipid-associated sialic acid: application for early diagnosis of colorectal cancer.
Tautu C; Verazin G; Prorok JJ; Alhadeff JA
J Natl Cancer Inst; 1988 Oct; 80(16):1333-7. PubMed ID: 3172258
[TBL] [Abstract][Full Text] [Related]
34. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
35. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
[TBL] [Abstract][Full Text] [Related]
36. How many lymph nodes should be examined in Dukes' B colorectal cancer? Determination on the basis of cumulative survival rate.
Yoshimatsu K; Ishibashi K; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Hepatogastroenterology; 2005; 52(66):1703-6. PubMed ID: 16334761
[TBL] [Abstract][Full Text] [Related]
37. Estimation of the number of metastatic lymph nodes in dukes' C colorectal cancer.
Fukushima T; Akagi Y; Murakami H; Ushijima M; Ogata Y; Shirouzu K; Murotani K
Anticancer Res; 2013 Jul; 33(7):2949-55. PubMed ID: 23780985
[TBL] [Abstract][Full Text] [Related]
38. Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: relationships with tumor recurrence and survival.
Rosati G; Chiacchio R; Reggiardo G; De Sanctis D; Manzione L
Tumour Biol; 2004; 25(5-6):258-63. PubMed ID: 15627889
[TBL] [Abstract][Full Text] [Related]
39. Serum sialic acid--an important cancer marker.
Tewarson SL; Mittal VP; Singh M; Gupta GP
Indian J Cancer; 1993 Sep; 30(3):125-31. PubMed ID: 8300142
[TBL] [Abstract][Full Text] [Related]
40. The impact of surgeon and pathologist on lymph node retrieval in colorectal cancer and its impact on survival for patients with Dukes' stage B disease.
Evans MD; Barton K; Rees A; Stamatakis JD; Karandikar SS
Colorectal Dis; 2008 Feb; 10(2):157-64. PubMed ID: 17477849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
